squamous cell lung cancer
Conditions
Interventions
Nab-Paclitaxel
Sponsors
Tottori University Faculty of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Diagnosis as squamous cell lung cancer by histology or cytology 2)Measurable lesion by CT 3)Histoly of 1 regime of chemotherapy 4)Performance Status(ECOG)=0 or 1 5)Predictable more than 3month survival 6)20 years old of age and older 7)Normal bone-marrow function, hepatic function, renal function 8)Normal Cardiac electrogram 9)Written informed consent about transfusion of blood or substance of specific biological origin 10)Written informed consent about enrollment of this clinical trial
Exclusion criteria
Exclusion criteria: 1) Patient with need of procedure for pleural effusion 2) History of hypersensitivity against albumin preparation 3) Patient with need of drainage procedure for cardiac effusion 4) Patient with symptomatic brain metastasis 5) Patient with severe complications. 6) Patients with interstitial pneumonia or pulmonary fibrosis diagnosed by chest X-ray 7) Female Patient in or having a chance or planning of pregnancy or breast feeding, 8) Male patient in planning to impregnate 9) Patient with active multiple cancers. 10) Patients with history of drug hypersensitivity 11) Patinets with histoly of hypersensitivity against Txeane agents include paclitaxel and docetaxel 12) Case which was judged as impossible to perform by physician in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease Control Rate(DCR) | — |
Secondary
| Measure | Time frame |
|---|---|
| Response Rate(RR), Overall Surivival(OS), Progress Free Survival(PFS), Safety | — |
Countries
Japan
Contacts
Public ContactHaruhiko Makino
Tottori University Faculty of Medicine Division of Medical Oncology and Molecular Respirology
Outcome results
None listed